Elanco Animal Health's (ELAN) Hold (C-) Rating Reaffirmed at Weiss Ratings

Key Points

• Elanco Animal Health has received a "hold (C-)" rating from Weiss Ratings, with additional reports from other analysts suggesting a range of ratings from "strong buy" to "neutral."
• The company's stock price currently stands at $20.34, with a 1-year low of $8.02 and a high of $21.76, indicating significant volatility over the past year.
• Elanco recently reported strong earnings for Q2, with $0.26 EPS exceeding estimates and quarterly revenue of $1.24 billion, contributing to positive forward guidance for FY 2025.

Elanco Animal Health (NYSE:ELAN - Get Free Report)'s stock had its "hold (c-)" rating reiterated by research analysts at Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.

ELAN has been the subject of several other research reports. Leerink Partners raised shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating and set a $18.00 price target for the company in a research report on Thursday, July 17th. Leerink Partnrs raised shares of Elanco Animal Health from a "hold" rating to a "strong-buy" rating in a research report on Thursday, July 17th. Piper Sandler increased their price objective on shares of Elanco Animal Health from $12.00 to $18.00 and gave the stock a "neutral" rating in a research report on Monday, August 11th. Wall Street Zen raised shares of Elanco Animal Health from a "hold" rating to a "buy" rating in a research report on Saturday, July 5th. Finally, Zacks Research upgraded shares of Elanco Animal Health from a "hold" rating to a "strong-buy" rating in a research note on Friday, October 3rd. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, Elanco Animal Health currently has a consensus rating of "Moderate Buy" and a consensus target price of $19.14.

Elanco Animal Health Price Performance

ELAN traded down $0.11 during midday trading on Wednesday, reaching $20.34. 5,237,886 shares of the company's stock were exchanged, compared to its average volume of 5,551,459. The company has a debt-to-equity ratio of 0.61, a current ratio of 2.60 and a quick ratio of 1.40. The stock has a market capitalization of $10.11 billion, a PE ratio of 23.65, a P/E/G ratio of 3.77 and a beta of 1.65. The business's 50-day moving average price is $18.11 and its 200 day moving average price is $14.27. Elanco Animal Health has a 1-year low of $8.02 and a 1-year high of $21.76.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $0.26 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.20 by $0.06. The company had revenue of $1.24 billion during the quarter, compared to analysts' expectations of $1.19 billion. Elanco Animal Health had a net margin of 9.68% and a return on equity of 7.04%. The firm's quarterly revenue was up 4.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.30 earnings per share. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. As a group, equities analysts anticipate that Elanco Animal Health will post 0.91 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in ELAN. Nuveen LLC bought a new position in Elanco Animal Health during the 1st quarter valued at $115,212,000. Dimensional Fund Advisors LP lifted its position in shares of Elanco Animal Health by 14.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 20,464,727 shares of the company's stock worth $214,875,000 after buying an additional 2,563,740 shares during the last quarter. Jennison Associates LLC lifted its position in shares of Elanco Animal Health by 322.0% in the 2nd quarter. Jennison Associates LLC now owns 3,234,717 shares of the company's stock worth $46,192,000 after buying an additional 2,468,122 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Elanco Animal Health by 104.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company's stock worth $50,268,000 after buying an additional 2,445,872 shares during the last quarter. Finally, ASR Vermogensbeheer N.V. bought a new position in shares of Elanco Animal Health in the 1st quarter worth about $23,744,000. 97.48% of the stock is currently owned by institutional investors.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.